Herantis Pharma Oyj (HRTIS) — Cash Flow-to-Debt Ratio
Herantis Pharma Oyj (HRTIS) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2025, meaning its operating cash flow of €-3.39 Million could theoretically repay -1% of its total liabilities (€3.36 Million) in one year. Explore Herantis Pharma Oyj strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Herantis Pharma Oyj Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Herantis Pharma Oyj across 13 annual periods. Also explore Herantis Pharma Oyj balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Herantis Pharma Oyj (2012–2024)
Year-by-year debt coverage analysis for Herantis Pharma Oyj. For market capitalisation and broader financial context, see Herantis Pharma Oyj market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.33x | €-6.54 Million | €2.81 Million | ▼ -1.3% |
| 2023 | -2.30x | €-4.64 Million | €2.02 Million | ▼ -61.5% |
| 2022 | -1.42x | €-8.94 Million | €6.29 Million | ▲ +8.9% |
| 2021 | -1.56x | €-9.93 Million | €6.36 Million | ▼ -61.1% |
| 2020 | -0.97x | €-8.56 Million | €8.83 Million | ▼ -50.0% |
| 2019 | -0.65x | €-5.96 Million | €9.22 Million | ▼ -25.3% |
| 2018 | -0.52x | €-3.73 Million | €7.24 Million | ▼ -48.5% |
| 2017 | -0.35x | €-2.60 Million | €7.48 Million | ▲ +1.2% |
| 2016 | -0.35x | €-3.04 Million | €8.63 Million | ▲ +61.5% |
| 2015 | -0.91x | €-7.40 Million | €8.09 Million | ▼ -63.1% |
| 2014 | -0.56x | €-4.36 Million | €7.77 Million | ▼ -530.5% |
| 2013 | -0.09x | €-224.21K | €2.52 Million | ▲ +63.1% |
| 2012 | -0.24x | €-533.42K | €2.21 Million | — |